Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
ERYTECH Pharma S.A. focuses on developing innovative treatments for cancer and rare diseases using its proprietary red blood cell technology. The company is primarily engaged in clinical trials for its lead product candidate, eryaspase, which targets specific cancer types, particularly in Europe and the U.S.
ERYTECH Pharma's business model is centered around the development and commercialization of its lead product, eryaspase, which is designed to improve the efficacy of chemotherapy by encapsulating drugs in red blood cells. The company has a unique competitive advantage due to its proprietary technology that enhances drug delivery and reduces side effects.
Clinical trial results for eryaspase, particularly Phase III outcomes in pancreatic cancer
Regulatory approvals from the FDA or EMA for eryaspase
Partnership announcements with larger pharmaceutical companies
Market sentiment around the biotechnology sector
Regulatory changes impacting drug approval processes
Technological disruption in drug delivery systems
Emerging therapies targeting the same cancer indications
Established biotech firms with more resources and pipeline depth
High cash burn rate with no current revenue generation
Potential dilution from future financing rounds
low - The biotechnology sector is generally less sensitive to economic cycles, as healthcare demand remains relatively stable regardless of economic conditions.
Moderate - Rising interest rates could increase the cost of capital for ERYTECH, impacting its ability to fund ongoing clinical trials and operations.
minimal - The company has a manageable debt-to-equity ratio of 0.52, indicating limited reliance on credit.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has shown significant price fluctuations, evidenced by a 32.0% return over six months followed by a -23.5% return over the past year.